HER2DX risk-score in early-stage HER2-positive breast cancer

Independent validation of the HER2DX genomic test in HER2-positive breast cancerПодробнее

Dr. Crew on Treatment in Favorable-Risk HER2+ Breast CancerПодробнее

#ESMO21 Expert Video Report on HER2-positive early breast cancerПодробнее

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients ...Подробнее

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancerПодробнее

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Update from KAITLIN for high-risk HER2-positive early breast cancerПодробнее

Ask the expert: Early-stage HER2-positive breast cancer with Adrienne Waks, MDПодробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее

Early Stage HER2+ Breast Cancer - Dr. Christy RussellПодробнее

Treatment for High- and Low-Risk HER2+ Breast CancerПодробнее

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Reduce the Risk of Recurrence in Early Stage HER2+ Breast CancerПодробнее

Adjuvant Therapy for Early-Stage HER2-Positive Breast CancerПодробнее

KATHERINE trial updates for HER2-positive breast cancerПодробнее

Treating Low-Risk HER2-Positive Breast CancerПодробнее

Preventing Recurrence: HER2-positive Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее